30 closest matches · ranked by relevance
Leukemia
Primary: Efficacy of GM-CSF and Pegylated Interferon-alpha 2b When Administered to Patients With AML, ALL, Blast Phase CML, and MDS Relapse After Allogeneic Transplantation…
Acute Myeloid Leukemia
Primary: Percentage of Participants With Complete Remission or Complete Remission With Incomplete Recovery Blood Counts — 11 percentage of participants
Alkylating Agent-Related Acute Myeloid Leukemia · Secondary Acute Myeloid Leukemia
Primary: Relapse-free Survival (RFS) — 21.5 Months
Adult Acute Megakaryoblastic Leukemia (M7) · Adult Acute Minimally Differentiated Myeloid Leukemia (M0) · Adult Acute Monoblastic Leukemia (M5a)
Primary: Achievability of Performing Individualized Drug Screening and Initiating Therapy Based on the Results of the Drug Screen for Poor Risk Patients With Relapsed or…
Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia · Recurrent Childhood B-Lymphoblastic Lymphoma
Primary: 3-year Overall Survival Rate of Patients With Relapsed ALL — 94.4; 55.5; 72.63 percentage of participants — p=0.035
Leukemia, Myeloid, Acute
Primary: Determination of the Maximum Tolerated Dose (MTD) of BI 836858 — NA; NA Milligram (mg)
Lymphoblastic Leukemia, Acute, Childhood · Myelogenous Leukemia, Acute, Childhood
Primary: The Dose of AC220 That is Safe and Biologically Active When Given in Sequential Combination With Ara-C/Etoposide — 0; 3; 1; 4 Participants
Recurrent Acute Leukemia of Ambiguous Lineage · Recurrent Acute Lymphoblastic Leukemia · Recurrent Acute Myeloid Leukemia
Primary: Percentage of Patients we Are Able to Test and Initiate Treatment Within a 21 Day Period — 21 Participants
Leukemia, Myeloid, Acute
Primary: Phase I Only - Maximum Tolerated Dose (MTD) as Measured by Dose-limiting Toxicities (DLTs) — 1; 0; 0 dose-limiting toxicities
AML
Primary: Complete Response Rate — 19 Participants
Leukemia
Primary: Number of Patients With Natural Killer (NK) Cell Expansion — 2 Participants
Relapsed Acute Myeloid Leukemia
Primary: Feasibility of a Novel Combination of Pembrolizumab and Decitabine in Relapsed/Refractory Acute Myeloid Leukemia Participants — 10 Participants
Acute Myeloid Leukemia · Acute Myeloid Leukemia, in Relapse · Acute Myeloid Leukemia Refractory
Primary: Maximum Tolerated Dose (MTD) — 5; 5; 2 participants
Acute Myeloid Leukemia · Acute Lymphoid Leukemia
Primary: Number of Participants According to Health Insurance Type — 265; 44; 253; 27 Participants
Leukemia
Primary: Number of Patients With Complete Remission — 3 participants
Recurrent Childhood Acute Lymphoblastic Leukemia
Primary: Remission Re-induction (CR2) Rate — .646; .660 proportion of participants
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome · Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 · Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11
Primary: Participants With a Response — 3 Participants
Acute Myeloid Leukemia
Primary: Number of Participants With Dose Limiting Toxicities — 0; 0; 0 Participants
Acute Myeloid Leukemia · Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities · Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Primary: Maximum Tolerated Dose of Clofarabine — 25 mg/m^2 of clofarabine
B Acute Lymphoblastic Leukemia · B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 · B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
Primary: Complete Response (CR or CRi) — 0 proportion of participants
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome · Recurrent Acute Myeloid Leukemia · Refractory Acute Myeloid Leukemia
Primary: Recommended Phase II Dose (RP2D) of 8-Chloro-adenosine (8-Cl-Ado) — 400 mg/m^2
Acute Myeloid Leukemia Post Cytotoxic Therapy · Recurrent Childhood Acute Myeloid Leukemia · Secondary Acute Myeloid Leukemia
Primary: Number of Participants With a Dose-limiting Toxicity — 1 Participants
Leukemia
Primary: Measure Patient Response to High-dose Cytarabine Followed by Clofarabine in Adult Patients With Relapsed or Refractory AML — 17 participants
Adult Acute Megakaryoblastic Leukemia (M7) · Adult Acute Minimally Differentiated Myeloid Leukemia (M0) · Adult Acute Monoblastic Leukemia (M5a)
Primary: The Rate of Complete Remission (CR+CRi) — 0.143; 0.278; 0.15 proportion of participants
Acute Lymphoblastic Leukemia
Primary: The Primary End-point is the Number of Patients in CR After Induction Therapy. — 9 Participants
Leukemia
Primary: Event-free Survival — 64.9; 70 percentage of participants
Leukemia, Myeloid, Acute · Leukemia, Lymphoblastic, Acute · Leukemia, Myelocytic, Chronic
Primary: Overall Recipient Survival at 6-month Post-relapse of Disease — 0; 4 participants
Leukemia
Primary: Complete Remission — 52 percentage of participants
Leukemia
Primary: Dose-limiting Toxicity — 0; 0 participants
Acute Leukemias
Primary: Rate of Complete Remission (CR) — 0; 0 Participants